NCT03312231: A reported trial by National Institute of Allergy and Infectious Diseases (NIAID)
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03312231 |
|---|---|
| Title | A Phase II Study in Healthy Adults 19 Years and Older to Assess the Safety, Reactogenicity and Immunogenicity of a Sanofi Pasteur A/H7N9 Inactivated Influenza Vaccine Administered Intramuscularly With or Without AS03 Adjuvant |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Feb. 14, 2018 |
| Completion date | Sept. 26, 2019 |
| Required reporting date | Sept. 25, 2020, midnight |
| Actual reporting date | Sept. 17, 2020 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | None |